These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
409 related articles for article (PubMed ID: 21958178)
1. The use of biologic agents in the treatment of ocular manifestations of Behcet's disease. Benitah NR; Sobrin L; Papaliodis GN Semin Ophthalmol; 2011; 26(4-5):295-303. PubMed ID: 21958178 [TBL] [Abstract][Full Text] [Related]
2. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625 [TBL] [Abstract][Full Text] [Related]
3. Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Arida A; Fragiadaki K; Giavri E; Sfikakis PP Semin Arthritis Rheum; 2011 Aug; 41(1):61-70. PubMed ID: 21168186 [TBL] [Abstract][Full Text] [Related]
4. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients. Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907 [TBL] [Abstract][Full Text] [Related]
5. [Anti-TNF-α in the treatment of uveitis in the Besançon Hospital]. Fery-Blanco C; Schwartz C; Gil H; Curlier E; Prati C; Delbosc B J Fr Ophtalmol; 2011 Dec; 34(10):697-702. PubMed ID: 21889230 [TBL] [Abstract][Full Text] [Related]
6. Current and future treatments for Behçet's uveitis: road to remission. Mesquida M; Molins B; Llorenç V; Hernández MV; Espinosa G; Dick AD; Adán A Int Ophthalmol; 2014 Apr; 34(2):365-81. PubMed ID: 23729309 [TBL] [Abstract][Full Text] [Related]
7. Adalimumab for sight-threatening uveitis in Behçet's disease. Mushtaq B; Saeed T; Situnayake RD; Murray PI Eye (Lond); 2007 Jun; 21(6):824-5. PubMed ID: 16601736 [TBL] [Abstract][Full Text] [Related]
8. Induction of regulatory T cells by infliximab in Behcet's disease. Sugita S; Yamada Y; Kaneko S; Horie S; Mochizuki M Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):476-84. PubMed ID: 20861484 [TBL] [Abstract][Full Text] [Related]
9. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects. Tognon S; Graziani G; Marcolongo R Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463 [TBL] [Abstract][Full Text] [Related]
10. [The treatment of recurrent uveitis with TNF-alpha inhibitors]. Falappone PC; Iannone F; Scioscia C; Grattagliano V; Covelli M; Lapadula G Reumatismo; 2004; 56(3):185-9. PubMed ID: 15470524 [TBL] [Abstract][Full Text] [Related]
11. Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study. Interlandi E; Leccese P; Olivieri I; Latanza L Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S58-62. PubMed ID: 25005224 [TBL] [Abstract][Full Text] [Related]
14. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents. Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743 [TBL] [Abstract][Full Text] [Related]
15. [Efficacy of adalimumab in Behçet's disease. Description of 6 cases]. Calvo Catalá J; Campos Fernández C; Rueda Cid A; González-Cruz Cervellera MI; Baixauli Rubio A; Pastor Cubillo MD Reumatol Clin; 2011; 7(4):258-61. PubMed ID: 21794828 [TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Theodossiadis PG; Markomichelakis NN; Sfikakis PP Retina; 2007; 27(4):399-413. PubMed ID: 17420690 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab. Leccese P; Latanza L; D'Angelo S; Padula A; Olivieri I Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S93. PubMed ID: 21813069 [No Abstract] [Full Text] [Related]
18. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Galor A; Perez VL; Hammel JP; Lowder CY Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of infliximab on the acute attack of uveitis. Alokaily F; Alsaleh S; Al-Balawi M; Al-Rashidi S Saudi Med J; 2010 Jan; 31(1):82-5. PubMed ID: 20062906 [TBL] [Abstract][Full Text] [Related]
20. New approaches in the treatment of Adamantiades-Behçet's disease. Pipitone N; Olivieri I; Cantini F; Triolo G; Salvarani C Curr Opin Rheumatol; 2006 Jan; 18(1):3-9. PubMed ID: 16344613 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]